000			01910 a2200517 4500
005			20250515194136.0
264		0	_c20100430
008			201004s 0 0 eng d
022			_a1776-260X
024	7		_a10.1007/s11523-009-0130-0 _2doi
040			_aNLM _beng _cNLM
100	1		_aRaymond, Eric
245	0	0	_aSunitinib paves the way for targeted therapies in neuroendocrine tumors. _h[electronic resource]
260			_bTargeted oncology _cDec 2009
300			_a253-4 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAngiogenesis Inhibitors _xtherapeutic use
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aBiomarkers, Tumor
650	0	4	_aCarcinoid Tumor _xdrug therapy
650	0	4	_aCell Line, Tumor
650	0	4	_aClinical Trials as Topic
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aErbB Receptors _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aIndoles _xtherapeutic use
650	0	4	_aKidney Neoplasms _xdrug therapy
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMelphalan _xtherapeutic use
650	0	4	_aNeovascularization, Pathologic _xprevention & control
650	0	4	_aNeuroendocrine Tumors _xdrug therapy
650	0	4	_aPancreatic Neoplasms _xdrug therapy
650	0	4	_aProcarbazine _xtherapeutic use
650	0	4	_aProtein Kinase Inhibitors _xtherapeutic use
650	0	4	_aProto-Oncogene Proteins c-kit
650	0	4	_aPyrroles _xtherapeutic use
650	0	4	_aSunitinib
650	0	4	_aVinblastine _xtherapeutic use
650	0	4	_aXenograft Model Antitumor Assays
700	1		_aFaivre, Sandrine
700	1		_aHammel, Pascal
700	1		_aRuszniewski, Philippe
773	0		_tTargeted oncology _gvol. 4 _gno. 4 _gp. 253-4
856	4	0	_uhttps://doi.org/10.1007/s11523-009-0130-0 _zAvailable from publisher's website
999			_c19297401 _d19297401